Zydus receives tentative approval from the USFDA for Clofarabine Injection
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated March 09, 2016 titled "Zydus receives tentative approval from the USFDA for Clofarabine Injection". Fixes Record Date for Interim Dividend
Cadila Healthcare Ltd has informed BSE that the Company has fixed March 18, 2016 as the Record Date for the purpose of Payment of Interim Dividend.Further, the interim dividend shall be paid to the members entitled thereto, on and from March 23, 2016. The Dividend cheques would be posted on or after March 23, 2016 and within 30 days from the date of declaration of dividend as provided in the Companies Act, 2013. Board declares Interim Dividend
Cadila Healthcare Ltd has informed BSE that the Board of Directors of the Company at its meeting held on March 08, 2016, has declared an interim dividend of Rs. 3.20/- [i.e. @ of 320%] per Equity Share on 102,37,42,600 Equity Shares of Rs. 1/- each of the Company for the financial year 2015-2016. Board to consider Interim Dividend
Cadila Healthcare Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on March 08, 2016, inter alia, to consider, declaration of Interim Dividend for the financial year 2015-16 and to fix the Record date.Further, as per Code of Conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window shall remain closed from March... Cadila Healthcare gains on USFDA nod for anti-diabetic drug
The company has received final approval from the USFDA for Glyburide and Metformin Hcl tablets USP Zydus receives final approval from the USFDA for Glyburide and Metformin Hcl Tablets USP
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated March 01, 2016 titled "Zydus receives final approval from the USFDA for Glyburide and Metformin Hcl Tablets USP". Zydus to commence supplies to the US market from its formulation manufacturing facility at SEZ
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated February 19, 2016 titled "Zydus to commence supplies to the US market from its formulation manufacturing facility at SEZ". Subdued growth outlook for Cadila
After FDA warning letter for its Moraiya unit, new product approvals after site transfers might take 2-3 quarters Cadila Q3 net up 38% at Rs 390 cr
The company had posted a net profit of Rs 282 in the same period of previous financial year. Results Press Release
Cadila Healthcare Ltd has submitted to BSE a copy of Results Press Release for the period ended December 31, 2015.